Open Access Highly Accessed Research article

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden

Khalid Abubaker12, Rodney B Luwor3, Hongjian Zhu3, Orla McNally14, Michael A Quinn14, Christopher J Burns5, Erik W Thompson26, Jock K Findlay147 and Nuzhat Ahmed1247*

Author Affiliations

1 Women’s Cancer Research Centre, Royal Women’s Hospital, 20 Flemington Road, Parkville, Melbourne, Victoria 3052, Australia

2 Department of Surgery, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria 3065, Australia

3 Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Melbourne, Victoria 3052, Australia

4 Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, Victoria 3052, Australia

5 Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3052, Australia

6 St Vincent’s Institute, Melbourne, Victoria 3065, Australia

7 Prince Henry’s Institute of Medical Research, Melbourne, Victoria 3168, Australia

For all author emails, please log on.

BMC Cancer 2014, 14:317  doi:10.1186/1471-2407-14-317

Published: 6 May 2014

Additional files

Additional file 1: Figure S1:

mRNA expression of CSC markers in control and paclitaxel treated ascites-derived tumor cells. RNA from the control and matching paclitaxel treated ascites-derived tumour cells was extracted cDNA was prepared and q-PCR for EpCAM, NANOG CD44, CD117, Oct4, JAGGED, STAT3 and E-cadherin was performed as described in the Methods. The resultant mRNA levels were normalized to 18S mRNA. The experiments were performed using five independent patient samples; the resulting mRNA results were then pooled for analysis. Significant variation is indicated by *P < 0.05.

Format: JPEG Size: 21KB Download file

Open Data

Additional file 2: Figure S2:

(A-B): Immunohistochemistry expression of Ki67, cytokeratin 7 (CK7) in mouse tumors generated from ip transplantation of control, paclitaxel, CYT387 and combination of CYT387 and paclitaxel-treated HEY cells. (A) Tumor sections were stained and scoring for the staining of Ki67 and CK7 was performed as described in Figure 11. Magnification 200X, scale bar = 10 μm. (B) Significant variations between the groups is indicated by **P < 0.01.

Format: JPEG Size: 127KB Download file

Open Data

Additional file 3: Figure S3:

H and E staining of control and treated HEY cell derived-tumor associated infiltrated organs in mice. 5 × 106 cells were injected ip in each mouse. Histological images of liver and pancreas showing infiltration of control, paclitaxel-treated, CYT387 and combination of paclitaxel and CYT387-treated HEY cells. Arrows indicate tumor cells invading the respective organs. Magnification 200×, scale bar = 10 μm.

Format: JPEG Size: 96KB Download file

Open Data